Yes

Alpha₁ Agonist; Ophthalmic Agent, Vasoconstrictor

Topical ocular vasoconstrictor; will temporarily relieve congestion, itching, and minor irritation, and to control hyperemia in patients with superficial corneal vascularity; treatment of nasal congestion; adjunct for sinusitis

C

Hypersensitivity to naphazoline or any component, narrow-angle glaucoma, prior to peripheral iridectomy (in patients susceptible to angle block)

Rebound congestion may occur with extended use; use with caution in the presence of hypertension, diabetes, hyperthyroidism, heart disease, coronary artery disease, cerebral arteriosclerosis, or long-standing bronchial asthma

1% to 10%:

Central nervous system: Dizziness, headache, nervousness

Gastrointestinal: Nausea

Local: Transient stinging, nasal mucosa irritation, dryness, rebound congestion

Ocular: Mydriasis, increased intraocular pressure, blurring of vision

Respiratory: Sneezing

Symptoms of overdose include CNS depression, hypothermia, bradycardia, cardiovascular collapse, apnea, coma

Following initiation of essential overdose management, toxic symptoms should be treated. The patient should be kept warm and monitored for alterations in vital functions. Seizures commonly respond to diazepam (5-10 mg I.V. bolus in adults every 15 minutes if needed up to a total of 30 mg; I.V. 0.25-0.4 mg/kg/dose up to a total of 10 mg for children) or to phenytoin or phenobarbital. Hypotension should be treated with fluids.

Increased toxicity: Anesthetics (discontinue mydriatic prior to use of anesthetics that sensitize the myocardium to sympathomimetics, ie, cyclopropane, halothane), MAO inhibitors, tricyclic antidepressants hypertensive reactions

Store in tight, light-resistant containers

Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction

Onset of decongestant action: Topical: Within 10 minutes

Duration: 2-6 hours

Elimination: Not well defined

Nasal:

Children:

<6 years: Intranasal: Not recommended (especially infants) due to CNS depression

6-12 years: 1 spray of 0.05% into each nostril every 6 hours if necessary; therapy should not exceed 3-5 days

Children >12 years and Adults: 0.05%, instill 1-2 drops or sprays every 6 hours if needed; therapy should not exceed 3-5 days

Ophthalmic:

Children <6 years: Not recommended for use due to CNS depression (especially in infants)

Children >6 years and Adults: Instill 1-2 drops into conjunctival sac of affected eye(s) every 3-4 hours; therapy generally should not exceed 3-4 days

May cause nervousness or dizziness

TCAs and MAOIs may potentiate the pressor response of decongestants; monitor for changes in response

No information available to require special precautions

No effects or complications reported

Do not use discolored solutions; discontinue eye drops if visual changes or ocular pain occur; notify physician of insomnia, tremor, or irregular heartbeat; stinging, burning, or drying of the nasal mucosa may occur; do not use beyond 72 hours

Rebound congestion can result with continued use

Solution, as hydrochloride:

Drops: 0.05% (20 mL)

Spray: 0.05% (15 mL)

Ophthalmic: 0.012% (7.5 mL, 30 mL); 0.02% (15 mL); 0.03% (15 mL); 0.1% (15 mL)